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Abstract
Preclinical development encompasses the activities that link drug discovery in the laboratory to
initiation of human clinical trials. Preclinical studies can be designed to identify a lead candidate from
several hits; develop the best procedure for new drug scale-up; select the best formulation;
determine the route, frequency, and duration of exposure; and ultimately support the intended
clinical trial design. The details of each preclinical development package can vary, but all have some
common features. Rodent and nonrodent mammalian models are used to delineate the
pharmacokinetic profile and general safety, as well as to identify toxicity patterns. One or more
species may be used to determine the drug's mean residence time in the body, which depends on
inherent absorption, distribution, metabolism, and excretion properties. For drugs intended to
treat Alzheimer's disease or other brain-targeted diseases, the ability of a drug to cross the blood
brain barrier may be a key issue. Toxicology and safety studies identify potential target organs for
adverse effects and define the Therapeutic Index to set the initial starting doses in clinical trials.
Pivotal preclinical safety studies generally require regulatory oversight as defined by US Food and
Drug Administration (FDA) Good Laboratory Practices and international guidelines, including the
International Conference on Harmonisation. Concurrent preclinical development activities include
developing the Clinical Plan and preparing the new drug product, including the associated
documentation to meet stringent FDA Good Manufacturing Practices regulatory guidelines. A wide
range of commercial and government contract options are available for investigators seeking to
advance their candidate(s). Government programs such as the Small Business Innovative Research
and Small Business Technology Transfer grants and the National Institutes of Health Rapid Access
to Interventional Development Pilot Program provide funding and services to assist applicants in
preparing the preclinical programs and documentation for their drugs. Increasingly, private
foundations are also funding preclinical work. Close interaction with the FDA, including a meeting
to prepare for submission of an Investigational New Drug application, is critical to ensure that the
preclinical development package properly supports the planned phase I clinical trial.
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Introduction
The drug development process is typically divided into
three major steps: discovery, preclinical development, and
clinical trial. The transition from discovery to preclinical
development is a continuum, and results of preliminary
pharmacology and toxicology testing often contribute to
lead drug candidate selection. The boundary between pre-
clinical development and clinical trial is sharply defined
by the filing of an Investigational New Drug (IND; Table
1 lists preclinical development acronyms) application,
which is required prior to initiation of the clinical trial.
The activities supporting an IND application are the sub-
ject of this overview. The adage 'begin with the end in
mind' is particularly appropriate for preclinical develop-
ment, as the resulting IND must support the planned clin-
ical trial design. For example, a clinical trial involving
daily chronic administration requires repeat-dose toxicity
studies in preclinical animal models.
Once a lead candidate is identified, a typical preclinical
development program consists of six major efforts: manu-
facture of drug substance (DS)/active pharmaceutical
ingredient (API); preformulation and formulation (dos-
age design); analytical and bioanalytical methods devel-
opment and validation; metabolism and
pharmacokinetics; toxicology, both safety and genetic tox-
icology and possibly safety pharmacology; and good man-
ufacturing practice (GMP) manufacture and
documentation of drug product for use in clinical trials
(Figure 1) The IND application summarizes the results of
the above activities for submission to the US Food and
Drug Administration (FDA). Table 2 outlines the general
organization of an IND application and lists many of the
relevant Code of Federal Regulations (CFR) sections for
each key component. These activities are seldom discrete
and sequential; rather, they are interrelated and often con-
current, with results from each activity informing the
Table 1: Preclinical development acronyms
ADME Absorption, distribution, metabolism, and excretion
API Active pharmaceutical ingredient: any component intended to furnish pharmacological activity or other direct effect in the diagnosis, 
cure, mitigation, treatment or prevention of disease.
CFR Code of Federal Regulations
CGMP, GMP (Current) good manufacturing practice
CMC Chemistry manufacturing and controls
CoA Certificate of analysis
CRO Contract research organization
CTM Clinical trial material
cmax Maximum plasma concentration
DP Drug product: finished dosage form (for example, tablet, capsule, solution) that contains an active drug ingredient, generally in 
association with inactive ingredients
DS Drug substance: any substance that is represented for use in a drug and that, when used in manufacturing, processing, or packaging 
of a drug, becomes an active ingredient or a finished drug form
FDA US Food and Drug Administration
FIH First in human
FRS Foreign related substances
GLP Good laboratory practice
HPLC High performance liquid chromatography
ICH International Conference on Harmonisation
IND Investigational New Drug application
MTD Maximum tolerated dose
NCE New chemical entity
NDA New drug application
NCI National Cancer Institute
NIA National Institute on Aging
NOAEL No observed adverse effect level
PIB Powder in bottle
PK Pharmacokinetics
RAID Rapid Access to Intervention Development (preclinical program)
SBIR Small Business Innovative Research (grant)
STTR Small Business Technology Transfer (grant)
TI Therapeutic Index
TK Toxicokinetic
tmax Time of maximum plasma concentration after dose administration
TTP Target product profileBMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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other steps as the drug candidate progresses through char-
acterization and optimization (Figure 2).
Preclinical development components
Target product profile
Stephen Covey's advice to 'begin with the end in mind'
from his bestseller The 7 Habits of Highly Effective People [1]
is also applicable to drug development. The goal in drug
development is FDA approval of a new drug application
(NDA) and prescribed use in the clinic. Many project
development teams find it helpful to develop a target
product profile (TPP) to guide preclinical development.
The TPP is a useful tool for delineating the required as well
as desired features of the new drug product, critical mile-
stones, and metrics to success. The TPP provides a frame-
work to ensure that the preclinical development program
supports the intended clinical trial design and therapeutic
use [2]. The contents of a TPP may vary from compound
to compound and from team to team, but each profile
generally includes therapeutic indication(s); market size,
competition, and differentiators; expected clinical use,
including key trial endpoints; drug target and mechanism
of action; patient age range; dose route, form, and fre-
quency of administration; bioavailability and duration of
action; safety, precautions, and contraindications; chem-
istry, manufacturing, and controls (CMC) profile, includ-
ing solubility, manufacturing process, formulation,
storage conditions, and stability; patent status and any
modifiers of exclusivity (for example, orphan drug status).
In the case of chronic neurodegenerative diseases such as
Alzheimer's disease, the unique medical needs of elderly
patients have the potential to affect several aspects of drug
design. Alleviation of Alzheimer's disease will most likely
require long-term treatment and, therefore, the preclinical
toxicology program must include repeat-dose administra-
tion to mimic the dosing regimen expected in the clinic.
Since Alzheimer's patients are generally well past child-
bearing age, some delay in safety testing for genetic and
reproductive toxicity potential is permitted. On the other
hand, it may be important to evaluate the potential for
drug-drug interaction much earlier in the drug develop-
ment program since many elderly patients are likely to be
prescribed medications to manage blood pressure, cardio-
vascular diseases, metabolic and digestive disorders, joint
inflammation, diabetes, and other conditions associated
with aging. Project teams may select a route and frequency
of dose administration that is optimal for compliance in
elderly Alzheimer's disease patients. For example, an oral
dose formulation composed of either small capsules/tab-
lets or a liquid to be administered once daily or less fre-
quently may be included in the TPP as a required product
feature. Many drugs targeting neurodegeneration such as
Table 2: IND application table of contents
1 Form FDA 1571 [21 CFR 312.23(a)(1)]
2 Table of contents [21 CFR 312.23(a)(2)]
3 Introductory statement [21 CFR 312.23(a)(3)]
4 General investigational plan [21 CFR 312.23(a)(3)]
5 Investigator's brochure [21 CFR 312.23(a)(5)]
6 Protocol(s) [21 CFR 312.23(a)(6)]
a. Study protocols [21 CFR 312.23(a)(6)]
b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)]a
c. Institutional review board data [21 CFR 312.23(a)(6)(iii)(b)]a
7 Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)]
8 Pharmacology and toxicology data [21 CFR 312.23(a)(8)]
9 Previous human experience [21 CFR 312.23(a)(8)]
10 Additional information [21 CFR 312.23(a)(10)]
aOr completed form(s) FDA 1572.
Preclinical drug development stages Figure 1
Preclinical drug development stages. Following identifi-
cation of a drug target and candidate compounds, several 
early activities, such as pharmacology, in vivo efficacy, and 
experimental toxicology, can contribute to the selection of a 
lead candidate for preclinical development. These preclinical 
activities provide the basis for an Investigational New Drug 
(IND) application to the FDA for permission to initiate clini-
cal testing in humans. ADME, absorption, distribution, 
metabolism, and excretion; API, active pharmaceutical ingre-
dient; PK, pharmacokinetics; Prep, preparation; Tox, toxicity.
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Preclinical flow diagram Figure 2
Preclinical flow diagram. The parallel and inter-related activities contributing to preclinical development are summarized 
with color coding to denote related components: manufacturing (red), analytical (grey), documentation (orange), safety (blue), 
clinical (green). API, active pharmaceutical ingredient; CMC, chemistry, manufacturing, and controls; FDA, US Food and Drug 
Administration; GLP, good laboratory practice; GMP, good manufacturing practice; ICF, informed consent form; IND, Investi-
gational New Drug; PK, pharmacokinetics.
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Alzheimer's disease will need to cross the blood brain bar-
rier to access the cellular target. Depending on the cellular
mechanism, bioavailability, particularly to the brain, at or
above a selected target concentration may be another
required feature delineated in the TPP.
The TPP document continues to evolve as the drug devel-
opment program progresses, and it should be regularly
reviewed by the team to assess whether required goals are
being met. Any results indicating potential safety concerns
or the inability of a given new chemical entity to fulfill
stated TPP criteria should be evaluated by the team for
their potential impact on project success. Implementation
of a TPP helps to keep the focus of the project on key prod-
uct criteria, thereby increasing the likelihood that 'Go/No-
Go' decisions will be made in a timely manner and reduc-
ing the overall project risk.
Pharmacology and experimental toxicology
The prelude to IND-enabling preclinical development
generally includes efficacy, pharmacology, and experi-
mental toxicology studies to define the dose, route, and
frequency required for subsequent studies. Using one or
more pharmacological animal models of the disease, the
initial efficacy studies demonstrate that treatment with
drug candidates has the desired therapeutic effect. Efficacy
studies also help to identify the best drug candidates for
further development. A number of studies are used to
address the absorption, distribution, metabolism, and
excretion (ADME) characteristics of the drug. Bioavailabil-
ity studies are generally conducted in vivo on candidates
intended to be administered by a nonintravenous route.
Bioavailability results provide information on the per-
centage of drug that is absorbed by the body as defined by
quantity in plasma. Pharmacokinetics (PK) studies pro-
vide information on the maximum attainable plasma
concentration (cmax), the time after dose administration to
cmax (tmax), the mean residence time in the plasma, clear-
ance, and other information used to characterize the
body's effect on the drug.
Initial dose range-finding and toxicity studies include sin-
gle- and multiple-dose administration protocols with var-
ied observation times. These earliest studies are intended
to determine the maximum tolerated dose (MTD), iden-
tify observable signs of toxicity, and provide a rationale
for setting dose levels in more complex definitive studies.
Regulatory requirements almost always call for definitive
studies in at least two laboratory animal species, one
rodent (rat or mouse) and one nonrodent (rabbit, dog,
nonhuman primate, or other suitable species). Prelimi-
nary toxicity, bioavailability, and PK studies should also
include one or more rodent and nonrodent species,
including the species to be used in the definitive studies.
The group sizes for the early range-finding studies may
consist of only a few animals and one sex (one animal per
dose level). Once a suitable dose range is identified, group
sizes are increased to at least three per sex per dose level to
allow for statistical comparisons. Only a few endpoints
are collected in these range-finding studies unless there
are particular toxicity concerns; a larger number of
required endpoints will be evaluated in the eventual
definitive studies described below. Although scientific
and reporting integrity is expected for any study, quality
assurance audit and review are rarely required for bioa-
vailability, PK, and range-finding studies.
Active pharmaceutical ingredient
API and DS are different terms for the same type of chem-
ical entity used in the FDA Guidance for Industry CGMP for
Phase 1 Investigational Drugs (2008) [3] and International
Conference on Harmonisation (ICH) document Q7: Good
Manufacturing Practice Guide for Active Pharmaceutical
Ingredients (2000) [4] and, therefore, these terms are used
interchangeably. According to the 2008 FDA guidance,
both of these designations refer to 'any substance or mix-
ture of substances intended to be used in the manufacture
of a drug (medicinal) product and that, when used in the
production of a drug, becomes an active ingredient of the
drug product. Such substances are intended to furnish
pharmacological activity or other direct effect in the diag-
nosis, cure, mitigation, treatment, or prevention of disease
or to affect the structure and function of the body.' APIs
include substances manufactured by processes such as
chemical synthesis, fermentation, recombinant DNA or
other biotechnology methods, isolation/recovery from
natural sources, or any combination of these processes.
Ultimately, the API must be well characterized in terms of
structure identity (crystalline or polymorphic), counter
ions (salts) and co-crystals, impurities, stability, chirality
and enantiomer(s), appearance, solubility, and other
chemical and physical properties. These properties will
continue to be referenced throughout API scale-up proc-
ess chemistry and GMP manufacturing.
All preclinical drug development programs require an
adequate drug supply. As development progresses,
increasing quantities of higher quality APIs are required
for small non-good laboratory practice (non-GLP) effi-
cacy studies, early formulation activities, in vivo dose
range-finding studies, and finally rigorous IND-enabling
GLP toxicology studies. For small molecule drugs, milli-
gram quantities of research grade material are usually suit-
able for early stage in vivo efficacy and ADME studies, as
well as small PK and dose range-finding studies (the latter
may require gram quantities).
When a molecular entity is selected, preformulation activ-
ities commence to determine its physical and chemical
properties, including counter ion salt or polymorphicBMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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form, solubility, and stability. The outcome of this stage is
a recommended form, and the API portion of the project
will transition to issues surrounding reaction efficiency,
cost of goods, purity and control of impurities, and batch-
to-batch consistency. In most cases the original medicinal
chemistry reaction must be refined to improve availability
of common starting materials and reaction reproducibil-
ity and scalability to maximize both product consistency
and yield for each batch. As each batch is scaled up to pro-
duce greater quantities (grams to kilograms), the analyti-
cal control assays will require more stringent tolerance
limits. Eventually these synthetic steps, along with control
documentation, will be written into the master batch
record and included in the IND package in the CMC sec-
tion. In addition, API stability and degradation, including
identity of major degradation products, will be evaluated
for a variety of storage conditions and documented in the
CMC section. These latter steps fall under GMP guidance
and are beyond the capabilities of most investigative
research laboratories. At some point in the process, the
investigator may opt to transfer the synthetic process
(along with appropriate legal intellectual property docu-
mentation) to a specialized contract research organization
(CRO) that will produce required batches along with a
Certificate of Analysis or GMP release for each batch.
Once an API batch is released, it is ready to be used in GLP
safety toxicology studies or prepared/formulated for clin-
ical use.
Formulation
Drug formulation, the mixing of API with other chemical
ingredients to create the drug product (DP), is often a
major hurdle in drug development. At this stage, the route
of administration intended for the clinic should be clearly
identified. Drugs may be introduced either enterally (oral,
buccal, and rectal) or parenterally (not through the ali-
mentary canal) including by injectable routes (intrave-
nous, intramuscular, and subcutaneous), topically, and
by inhalation. Except for imaging diagnostic agents, vac-
cines, and antibodies, most drugs targeting neurodegener-
ative diseases and their symptoms will be administered by
the enteral or possibly topical routes. Drugs intended to
be administered orally may be formulated as a solution,
suspension, capsule, or tablet. Any formulation intended
for human use is subject to rigorous quality control man-
ufacturing and safety testing.
In addition to the clinical application, the specific physic-
ochemical properties of a DS will influence formulation
options. A number of parameters must be considered
when creating the DP formulation. The components of
any formulation must have physical and chemical com-
patibility with the DS. Patient factors to consider include
tablet/capsule size, taste, stability and shelf life, and ease
of use. Formulations may incorporate components such
as dissociation enhancers that are found to improve bioa-
vailability of the active DS. Solid formulations, particu-
larly tablets, may be coated to improve swallowing, mask
an unpleasant taste, protect ingredients during storage,
improve appearance, and control drug release over time
or target it to specific regions of the gastrointestinal tract.
In most instances, the clinical drug formulation is not
fully optimized before submission of the IND and the ini-
tial first-in-human (FIH) clinical studies. Therefore, it is
customary to compose a simple formulation to be pre-
sented as the DP in the IND and used in phase1 studies to
deliver the drug to human subjects. For example, an oral
FIH trial design may utilize drug supplied as a powder; an
appropriate quantity is weighed out by the pharmacist
and placed in a gelatin capsule prior to administration.
For both oral and intravenous FIH trial designs, a specific
amount of drug may be supplied in a clinical vial (also
known as powder in bottle, or PIB) to which the appropri-
ate volume of vehicle (specific liquid component) is
added prior to administration. These approaches are most
useful for early phase 1 trials involving relatively few
human subjects. As the clinical trials become more com-
plex and involve more subjects, oral formulations may be
prepared in tablets or capsules containing scaled quanti-
ties, or 'strengths,' of the drug (for example, 50 mg, 100
mg, and 200 mg) so that each patient can take a combina-
tion of quantities to target individual body weight. Once
the unit dose is established (usually after phase 2 and
before phase 3 clinical trials), a formulation is selected as
the final DP for later stage clinical trials and product
release. As described above for APIs, all formulations
intended for human use are prepared under rigorous spec-
ifications as outlined in the GMP guidelines.
Analytical and bioanalytical methods
Starting from the initial drug discovery phase, analytical
chemistry applications are found throughout the drug
development process. These applications can be catego-
rized into two major subdivisions: pharmaceutical analy-
sis and bioanalysis. Pharmaceutical analysis involves the
measurement of an analyte in a neat sample or formula-
tion, whereas bioanalysis is the quantification of an ana-
lyte in a biological matrix.
Analytical methods
Reliable analytical methods are required to test and qual-
ify in-coming materials, in-process methods, equipment,
formulations, DSs, and DPs. These methods are critical for
analyzing the various formulations that may be investi-
gated for a final dosage form and are integral to quality
control in GLP and GMP settings. In addition, FDA and
ICH guidelines require stability testing on each lot of DS
and DP. Therefore, analytical methods may need to be
developed for a variety of materials and circumstances,BMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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each with a different intended purpose. For example, the
analytical method required for formulation development
may not require the same performance characteristics as
those required for a stability-indicating method for DS or
DP. Analytical work consists of two components: a
research and development component and a GLP/GMP
component. The research and development component
includes analytical method development and analytical
support for preformulation and formulation. The rest of
the analytical work is conducted according to GLP and
GMP guidelines. The quality control unit is responsible
for the oversight of GMP analytical work.
It is essential that the validated methodology used to test
the DS be used in clinical manufacturing. The developed
method must satisfy two requirements: it must be accu-
rate, requiring high specificity, good precision, and good
reproducibility; and it should be practical, with the neces-
sary ruggedness, sensitivity, and linearity. Assay methods
are verified under the ICH guidelines for reproducibility,
specificity, selectivity, accuracy, linearity, precision, appli-
cable concentration range, limit of detection, limit of
quantification, ruggedness, and robustness. The specifica-
tions for DS typically include a physiochemical character-
ization program that generally requires determination of
the composition, physical properties, and primary struc-
ture of the desired product.
The suitability of a final compound for pharmaceutical
use requires establishment of its identity and purity, as
well as knowledge of its chemical and physical properties.
Formulation analysis verifies the active and inactive com-
ponents and dosage, assesses potency, determines shelf-
life stability, confirms dissolution properties, and deter-
mines whether decomposition has occurred or impurities
have been introduced during the formulation process. It is
important to ensure that materials of known purity and
defined quality are used in all studies and that they con-
form to applicable FDA regulatory requirements.
Bioanalytical methods
Physiologic fluids such as blood, plasma, and urine are
analyzed to determine the fate and disposition of a DS
administered to a test animal or patient. Aliquots of blood
may be sampled over time to determine therapeutic drug
concentration ranges. Often the goal is to assess the over-
all ADME characteristics of the DS. The concentration of
the drug in the biological matrix changes with time, typi-
cally over a broad range, and, therefore, bioanalytical
quantification limits are at concentrations much lower
than those required for formulated or bulk drugs. An
appropriate bioanalytical method is required to detect
drug at these low levels, as well as linearly over an appro-
priate range. Matrix effects and stability issues can also
make accurate analysis of the analyte difficult; these
include, among many others, endogenous materials
extracted from the biological matrix that may interfere in
the analysis, enzymes in the biological fluid that are capa-
ble of metabolizing the analyte, plasma proteins that the
analyte can bind to, and concomitant drugs that might
interfere in the analysis. All these factors must be consid-
ered when planning an analysis.
Pharmacokinetics, toxicokinetics, and metabolism
PK, or the study of the time course of a drug in the body
incorporating the processes of ADME, is a key determi-
nant in the selection of a viable drug candidate. Since
many potential drugs are eliminated from further devel-
opment because of poor PK properties, drug discovery
programs now incorporate early ADME screens for desira-
ble 'drug-like' properties to optimize the selection of suc-
cessful candidates. These predictive ADME approaches
include in silico models, physiochemical parameters, and
in vitro assays of permeation and drug metabolism to bet-
ter evaluate the properties of potential pharmaceuticals
and to concentrate additional efforts on only the most
promising compounds. After these screening data are
evaluated in concert with efficacy results, compounds that
are predicted to have favorable PK properties are studied
further using in vivo animal models.
PK parameters are extrapolated from measurements of
drug concentration in the plasma, blood, or other relevant
biological matrix over a selected time period (usually sev-
eral time points concluding at 24 or 48 hours post dose).
PK provides information that can guide future animal and
clinical studies for the selection of the dose levels and fre-
quency of administration. The IND package requires PK
data generated in two species (one rodent, one nonro-
dent), preferably using the same two species used for the
safety studies. These studies usually include multiple dose
levels so that PK dose dependency can be evaluated. Oral
and intravenous administrations are compared to deter-
mine the oral bioavailability of the drug if an oral route is
anticipated for the clinic. It is not necessary to delineate all
ADME characteristics of a molecule at the time of IND
submission, since the first clinical study generally focuses
on the pharmacokinetics and metabolism of the drug in
humans.
Toxicokinetic (TK) endpoints are similar to PK except that
the samples are collected from animals during the toxicol-
ogy and safety studies (described below) and usually do
not cover as many time points. They help the investigator
understand the drug's behavior at the maximal dose levels
used in toxicology studies as well as steady state, accumu-
lation, and trough levels after repeated administration.
The same bioanalytical methods as developed for in vivo
PK evaluations are usually suitable for measuring drug
concentration in the relevant biological matrix (for exam-BMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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ple, plasma); however, the method will need to be vali-
dated if it is applied to GLP study samples.
Metabolism studies are also recommended by the FDA.
These studies can be useful to evaluate the potential for
drug-drug interactions and cytochrome P450 inhibition
and to generate drug metabolite profiles for different spe-
cies, including humans. Metabolism studies are typically
conducted using in vitro methods for exposing hepatic
microsomes, cytosolic fractions, hepatocyte cultures, or
other applicable test systems to the drug. Using a bioana-
lytical method, any metabolites are described as a frac-
tional percent of parent-drug peak. Any metabolite
occurring at a significant level (for example, accounting
for 10% or more of parent drug level, particularly when
using test systems derived from primary human tissues)
likely represents a significant metabolic pathway for the
drug and may require further investigation, including elu-
cidation of metabolite identity and biological activity. In
vitro metabolism studies are frequently the first glimpse
into the effects of human metabolic pathways on a drug
and may reveal considerable metabolic differences
between humans and preclinical species. In the event of
significant interspecies metabolite profile differences,
investigators may compare these with the human metab-
olite profile to identify which species, if any, most closely
matches the humans, and then select this species for the
pivotal safety and toxicology studies. Because of the
importance of these interspecies results for understanding
the potential disposition of the drug in humans, many
development plans begin these studies about the same
time as the first animal PK studies.
Pivotal toxicology and safety
Despite numerous technical advances in the science of
toxicology and attempts to develop in silico screening, the
primary methods used to assess safety remain single- and
repeat-dose toxicology studies conducted in rodent and
nonrodent species. Definitive animal studies establish the
safety characteristics, including the no observable adverse
effect level (NOAEL), of the candidate drug. With very few
exceptions, these studies are rigorously documented and
conducted under regulatory guidelines – for example,
FDA GLP. The highest dose levels tested in the definitive
animal studies are almost always based on the maximum
tolerated dose determined from the range-finding studies
rather than either the expected dose level to be used in the
clinical trial or an expected plasma concentration. By the
time a drug reaches definitive animal safety testing, a
human trials clinician is included in the drug develop-
ment team to provide study details on the proposed FIH
clinical trial. In general, the route and frequency of drug
administration, vehicle, and dose formulation (if applica-
ble) to be used in initial human trials is reflected in the
definitive animal studies.
To account for differences between humans and labora-
tory species, a safety margin is established based on the
NOAEL in the 'most sensitive' of the tested species. Toxi-
cology studies are commonly conducted in rats and dogs,
though other large animal species may be appropriate for
specific products or therapeutic applications. For exam-
ple, rabbits are frequently the species of choice for safety
testing of vaccines. Preliminary toxicity studies are often
performed as part of the lead compound selection proc-
ess. For IND-directed safety studies, two complete GLP-
compliant safety studies are generally required. The route
of administration in these studies must be the same as the
proposed clinical route. If the proposed route is oral, drug
is administered by gavage to rats and by gavage or capsule
to dogs. The duration of administration and dose regimen
must, at a minimum, conform to the proposed clinical
protocol. For example, if 14 days of continuous drug
administration is proposed for the phase 1 clinical trial,
then animal toxicity studies of at least 14 to 28 days are
typically required to support a clinical study of this length.
Although usually occurring after phase 1 dosing, longer
term animal studies (for example, 60 days and longer)
will be needed to support later stage human clinical trials.
The frequency of dosing (for example, three times a week
for 4 weeks) in the animal studies should also mimic the
clinical dosing schedule.
Pivotal safety studies are performed with drug manufac-
tured under GMP conditions whenever possible, although
the FDA does not state this requirement. In the event that
a drug is not manufactured under GMP conditions, the
investigator is required to demonstrate that the clinical
drug is essentially the same as that used in animal safety
studies. If significant differences (for example, different
counterion salts) are observed between GMP materials
scheduled for the clinic and the materials used in a pivotal
preclinical safety study, the regulating agency may deem
the safety study to be invalid and request that bioequiva-
lency studies be conducted or the pivotal study be
repeated using the correct materials. One strategy used by
some investigators to preemptively qualify some of the
possible manufacturing impurities, such as enantiomers
or side reactions, that may be present in batch production
is to utilize a batch in the animal studies that contains at
least 95% purity of the drug and up to 5% impurities.
Because most repeat-dose toxicity studies of therapeutics
reveal some adverse effects at higher dose levels, group
assignment also includes a recovery group to evaluate
whether adverse effects are transient or irreversible after
repeat dosing. For dose level selection, allometric body
surface area scaling may be used to convert from many
preclinical species to human dose levels, with additional
multiples added to account for interspecies differences
and potential safety factors.BMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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In addition to the pivotal safety studies, required ancillary
studies, specified in ICH guidelines, complete most regu-
latory packages. Safety pharmacology studies are required
regulatory elements outlined in ICH guideline S7A [5].
Standard procedures are established for the safety phar-
macology core battery, which includes assessments for the
central nervous system, cardiovascular system, and respi-
ratory system. Genetic toxicology studies, outlined in ICH
guidelines S2(R1) [6], are required for most small mole-
cules. The FDA requires submission of data from three
genetic toxicology assays for most IND applications: gene
mutation in bacteria, including four strains of Salmonella
typhimurium and one strain of Escherichia coli (Ames test);
an in vitro mammalian cell assay (either evaluation of
chromosomal damage in Chinese hamster ovary cells or
the mouse lymphoma mutagenesis assay); and in vivo
chromosomal damage in rat or mouse hematopoietic cells
(such as the rodent bone marrow micronucleus assay). If
the candidate drug may have immunosuppressive effects
identified in earlier toxicity or safety studies, ICH guide-
line S8 [7] provides an overview of follow-up programs.
Other studies that are frequently required in later stage
drug submissions (after phase 1 clinical studies) include
carcinogenicity and reproductive toxicology studies.
Pre-IND meeting
Prior to the preparation of an IND application, it is recom-
mended that the drug submitter request a pre-IND meet-
ing. This meeting gives the drug submitter an opportunity
to present the proposed preclinical and clinical trial pro-
tocols, as well as the proposed manufacturing and control
testing of the DS and DP, to the appropriate FDA division
representative(s). It also begins a dialog with the FDA to
address specific questions concerning the proposed pre-
clinical drug development program and its relation to the
proposed early stage clinical trial(s). These discussions
should occur prior to the initiation of complex preclinical
activities (for example, GLP multiple-dose studies) to
ensure that the design of the preclinical program
addresses any potential concerns posed by the FDA. Incor-
porating this step into the process greatly improves the
likelihood that the clinical trial will proceed within the
planned timeframe following the IND submission. The
pre-IND meeting request is accompanied by a background
document authored by the submitter and sent to the
reviewing agency that follows the FDA IND guidance. The
submitter includes as much of the required information as
possible by outlining completed, ongoing, and future
drug development activities expected to occur prior to the
clinical trial. Very importantly, the pre-IND document
also includes a proposed agenda and a list of specific ques-
tions from the submitter to the FDA. The pre-IND materi-
als include background information on the proposed use
of the drug candidate and the results of the studies to
determine its efficacy, summaries of the CMC process
(including flowcharts), the proposed preclinical safety
testing plan (current and future), the proposed phase I
clinical trial(s) design, as well as any and all results col-
lected to date. A response from the FDA is usually received
within 10 working days following the meeting request,
and if the FDA agrees to the request, the meeting usually
occurs within 60 days of the submission. Following the
pre-IND meeting, the preclinical development plan may
be revised by the submitter to address any concerns
expressed by the FDA.
IND submission
The IND application submitted to the FDA describes all of
the components in the development of the candidate
drug. The details of the required content and format are
described in detail in CFR title 21 part 312 [8] and FDA
'Guidance for Industry: Content and Format of Investiga-
tional New Drug Applications (INDs) for Phase 1 Studies
of Drugs, Including Well-Characterized, Therapeutic, Bio-
technology-derived Products' [9]. As per these guidance
documents, the contents include: a cover sheet; a table of
contents; an introductory statement and general investiga-
tional plan; an investigator's brochure – a compilation of
the clinical and nonclinical data on the investigational
product(s) that are relevant to the study of the product(s)
in human subjects (ICH E6(R1) [10]); protocols – sub-
mission of a copy of the protocol for the conduct of each
proposed clinical trial; chemistry, manufacturing, and
control information; pharmacology and toxicology infor-
mation; and previous human experience with the investi-
gational drug.
The submission is formally identified using form FDA
1571, which provides details about the drug submitter
and a checklist indicating the contents of the current FDA
submission. Within 30 days of the IND submission, the
FDA may put the clinical trial on hold or request addi-
tional data prior to the start of the study. If the submitter
does not receive a reply within the 30-day timeframe, the
trial may begin. At that time or prior to the start of the
study, form FDA 1572 must be sent to the FDA. This form
is completed by each clinical investigator at each clinical
site and provided for submission to the FDA using the
IND reference number. After the initial IND submission,
the IND is updated through amendments, safety reports,
or an annual report. Each update is accompanied by a
form FDA 1571 identifying the subject of the current sub-
mission.
Preclinical funding sources
The transition from research and preclinical development
to the clinic is so perilous that it is frequently referred to
as the 'Valley of Death' [11,12] (Figure 3). Funding chal-
lenges contribute to this bleak landscape. Successful tran-
sitioning often requires a combination of both privateBMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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and public sector investments targeting the most promis-
ing drug candidates. Several public and private sources are
available to provide funding for preclinical activities
(Table 3)
As part of its Roadmap for Medical Research Initiative, the
US Government provides resources for nonprofit and
commercial institutions through the NIH Rapid Access to
Interventional Development (RAID) pilot program and
the Small Business Innovative Research (SBIR) and Small
Business Technology Transfer (STTR) programs. The RAID
program is an NIH Roadmap initiative modeled after the
National Cancer Institute (NCI) RAID program. The RAID
programs are not grant-equivalent funding sources.
Rather, they provide access to NIH contract resources to
support preclinical development of small molecule drug
candidates. Potential services may include bulk API syn-
thesis and supply; GMP manufacturing of clinical supply;
formulation development; analytical assays; and develop-
ment and validation of animal PK, toxicology, and safety
tests. Currently, the RAID program does not fund devel-
opment of biologics, in vitro or in vivo efficacy testing, or
mechanism-of-action studies. Support for contracted pre-
clinical activities comes from the budgets of the NIH
Roadmap as well as the sponsoring NIH institute. This
program is currently available to investigators at aca-
demic, nonprofit, and SBIR-eligible (see below) institu-
tions. Additional information is available at the NIH
RAID program web site [13] and from program officers at
appropriate NIH institutions.
Cash flow 'Valley of Death' diagram Figure 3
Cash flow 'Valley of Death' diagram. The cash flow 'Valley of Death' as a function of development stage (time) with typical 
funding sources at various stages (adapted from [12]). RAID, Rapid Access to Interventional Development; SBIR, Small Business 
Innovative Research; RAPID, Rapid Access to Preventive Intervention Development; STTR, Small Business Technology Trans-
fer.
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Although RAID support is limited to developing small
molecules, other promising approaches such as biologics,
vaccines, antibodies, and other non-small-molecule ther-
apies have access to preclinical PK and toxicology testing
services through STTR, SBIR, and institute-sponsored pro-
grams. The SBIR and STTR programs (R43, R44, R41, and
R42) are designated for domestic small (<500 employees)
businesses to support commercialization of discoveries
and inventions. Eligibility is currently restricted to compa-
nies that are at least 51% owned by one or more individ-
uals who are US citizens or permanent resident aliens. In
the SBIR program, the primary employer of the Principal
Investigator must be an established small business. In
contrast, the STTR funds partnerships between an aca-
demic or nonprofit institution and a small company with-
out restrictions on the employer of the Principal
Investigator. Phase I SBIR and STTR programs are
intended to test the technical feasibility and commerciali-
zation potential of proposed research and development
projects. Phase II awardees receive further funding and
time to develop the lead, although the funds are usually
not adequate to support a full preclinical program. In
early 2008, the NIH offered phase II SBIR awardees an
additional opportunity to apply to the Manufacturing
Assistance Program for help in overcoming manufactur-
ing issues.
In addition to the above NIH funding resources, many
NIH institutes offer funding through 'Cooperative Agree-
ment Research Project Awards' (U01) to academic, not-
for-profit, and other entities. These awards support a dis-
crete, specified, circumscribed research project to be per-
formed by the named investigators in cooperation with
NIH program staff and are milestone driven for continued
funding to reach an IND filing.
In addition to government-funded programs, public and
private foundations offer funding, outsourcing, and other
resources for translational development [14,15]. Table 3
lists web links for several foundations that support pre-
clinical development for neurodegenerative diseases. The
Alzheimer's Drug Discovery Foundation (ADDF) was
established in 2004 by the Institute for the Study of Aging
to support drug discovery research for Alzheimer's and
related diseases. ADDF preclinical support includes fund-
ing for drug discovery and development and sponsorship
of forums to share best practices. The Amyotropic Lateral
Sclerosis Association launched the Translational Research
Advancing Therapy for Amyotropic Lateral Sclerosis
(TREAT ALS) initiative to accelerate drug development
and support clinical trials. To support rapid development
of treatments for multiple sclerosis, the National Multiple
Sclerosis Society founded Fast Forward in 2007 as a
wholly owned nonprofit subsidiary. Its purpose is to fund
preclinical studies leading to clinical trials, support star-
tup and existing companies, and repurpose existing drugs
as potential multiple sclerosis therapeutics. The Myelin
Repair Foundation supports drug development focused
on re-myelination of multiple sclerosis lesions and has
organized a consortium of leading labs from multiple uni-
versities to collaborate on therapies that repair damaged
myelin. The High Q Foundation established CHDI Foun-
dation, Inc. as a virtual biotechnology company to dis-
cover and develop drugs targeting Huntington's disease.
The Michael J Fox Foundation for Parkinson's Research
(MJFF) supports drug development through several fund-
Table 3: Preclinical development funding links
NIH programs
RAID pilot program http://nihroadmap.nih.gov/raid
SBIR/STTR http://grants.nih.gov/grants/funding/sbir.htm
Alzheimer's disease
Alzheimer's Drug Discovery Foundation http://www.alzdiscovery.org
Amyotropic lateral sclerosis
Amyotropic Lateral Sclerosis Association http://www.alsa.org
Huntington's disease
CHDI, Inc. http://www.chdi-inc.org
High Q Foundation http://www.highqfoundation.org
Multiple sclerosis
National Multiple Sclerosis Society http://www.nationalmssociety.org
Myelin Repair Foundation http://www.myelinrepair.org
Parkinson's disease
Michael J Fox Foundation for Parkinson's Research http://www.michaeljfox.org
RAID, Rapid Access to Interventional Development; SBIR, Small Business Innovative Research; STTR, Small Business Technology Transfer.BMC Neurology 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1471-2377/9/S1/S2
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ing mechanisms, including Rapid Response Innovation
Awards with a rolling application to support novel
research proposals, a Target Validation program, Novel
Approaches to Parkinson's Disease Drug Discovery in
partnership with Elan Pharmaceuticals, and the LEAPS
Initiative to support a team approach to major develop-
mental challenges. The MJFF Therapeutics Development
Initiative exclusively funds biotechnology and pharma-
ceutical companies to support drug and biomarker devel-
opment. This partial list of foundation initiatives
illustrates the variety and strength of support for preclini-
cal development available to fill critical gaps in expertise
and financial resources.
Outsourcing
Unlike large pharmaceutical companies, most academic
laboratories and small or virtual start-up companies lack
the facilities, expertise, and regulatory oversight to com-
plete the preclinical development testing required to file
an IND. These organizations frequently employ the serv-
ices offered by preclinical CROs. Under a contract with the
drug submitter, preclinical CROs, such as SRI Interna-
tional, Covance, and Charles River Laboratories, will per-
form individual tasks and studies or offer a full
development package. Some CROs have contracts with
NIH institutions (for example, the National Institute on
Aging (NIA)) to perform specific preclinical tasks for a
submitting investigator in response to a request from the
NIH Project Officer. In other cases, a CRO may be
included as a subcontractor under an SBIR grant or as a
designated partner under a foundation grant.
Conclusion
Drug development through IND submission requires
effective communication and execution by a team with a
diverse skill set. The progressive transition of a drug can-
didate from early to late preclinical stages is particularly
critical. Team members need to understand the intended
clinical plan for a drug candidate and anticipate potential
problems to execute an effective preclinical strategy. The
TPP provides a framework for defining the desired fea-
tures of the new DP, known or suspected risks and liabil-
ities, and metrics of success.
Despite careful planning, most drug candidates fail. Rea-
sons for failure include poor solubility, life threatening or
other undesirable side effects, poor biodistribution by the
proposed clinical route of administration, prohibitive
scale-up and manufacturing costs, market competition,
and poor efficacy in early clinical trials. The best that any
project team can do is set clear 'Go/No-Go' criteria and
design a preclinical strategy focused on identification of
key issues to weed out problematic drug candidates early
in the process. Preclinical drug development is often
called the 'Valley of Death,' where good ideas often die
through design flaws, lack of specialized expertise, and
insufficient funding. Increasingly, public and private
organizations are coming to the aid of investigators with
outsourcing and funding support (Table 3).
The 'Graying of America' [16] is upon us. Treating the
growing number of patients afflicted with neurodegener-
ative diseases threatens the resources of our health care
system, the financial stability of our country, and the qual-
ity of life for patients and their caregivers. More than ever,
effective navigation through the path of preclinical devel-
opment is essential for the pharmaceutical industry and
for society.
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